Close
Enter your
text here

CRISPR

CD38-CAR NK Cell Therapy Has Antitumor Potential for Treating CD38-Expressing Hematologic Malignancies
 CD38-CAR NK Cell Therapy Has Antitumor Potential for Treating CD38-Expressing Hematologic Malignancies 1024 649 Jessica Nye, PhD
By: Jessica Nye, PhD

Investigators from Nationwide Children’s Hospital created fratricide-resistant and metabolically-enhanced chimeric antigen receptor (CAR) natural killer (NK) and T cells that have cytotoxic effects on many hematologic tumors. “One of the problems that we usually have with blood cancers is making effective therapies using immune cells, because the immune cells then recognize themselves as a threat…

Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD
 Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD 150 150 Katie Brind'Amour, PhD, MS, CHES
By: Katie Brind'Amour, PhD, MS, CHES

Meisam Naeimi Kararoudi, DVM, PhD, director of the CRISPR/Gene Editing Core and principal investigator in the Center for Childhood Cancer Research at Nationwide Children’s, has taken a winding, international road to his current role at Nationwide Children’s Hospital. From his native Iran to Italy, England, Sweden and the United States, Dr. Naeimi Kararoudi has collected…

Investigators Develop Technique to Effectively Edit NK Cells to Target Specific Cancer Cells
 Investigators Develop Technique to Effectively Edit NK Cells to Target Specific Cancer Cells 1024 649 Katie Brind'Amour, PhD, MS, CHES
By: Katie Brind'Amour, PhD, MS, CHES

The third of three major challenges in enabling the clinical potential of NK cells for cancer therapy has just been addressed, thanks to the combined talents of gene editing experts and NK cell specialists at Nationwide Children’s Hospital.   Originally, NK cells seemed promising for a natural therapy to fight cancer due to their innate…